银屑病药物市场按药物类别、给药途径、患者严重程度、银屑病类型、患者类型、分销渠道和治疗环境划分 - 全球预测 2025-2032

预计到 2032 年，牛皮癣药物市场将成长至 276.3 亿美元，复合年增长率为 12.41%。

主要市场统计数据
基准年2024年	108.3亿美元
预计2025年	121.8亿美元
预测年份：2032年	276.3亿美元
复合年增长率（%）	12.41%

权威介绍，总结了当前的治疗方法、系统性压力以及影响牛皮癣药物开发和商业化的战略问题

银屑病药物领域已进入一个由快速的科学进步和不断变化的商业性动态所定义的阶段。生物目标和口服小分子药物的进展正在扩大治疗选择，并提高了人们对疗效提升、缓解持久性和患者便利性的期望。同时，付款人审查、供应链复杂性以及不断变化的监管要求迫使製造商和医疗保健提供者调整其营运和商业性模式。因此，产业相关人员必须将临床前景与实际考虑因素（例如生产扩充性、现实世界安全监测以及差异化的价值沟通）相协调。

本引言摘要了目前的治疗方法、主要的临床和商业性压力以及公司、临床医生和付款人目前面临的策略问题，为后续分析组装。它概述了治疗类别、给药途径、患者严重程度、银屑病亚型、患者人口统计、通路和治疗环境如何影响路径和长期治疗模式。透过将近期创新置于现实的实施约束条件下，本节旨在帮助读者评估策略选择、预测营运瓶颈，并确定能够带来持续临床和商业性回报的投资优先顺序。

变革性的临床、监管和商业转变正在汇聚，重新定义银屑病治疗的差异化治疗方法、获取途径和价值展示

科学突破、监管变革以及患者对个人化治疗的期望正在重塑银屑病治疗的模式。针对白细胞介素路径的生物製药和口服标靶抑制剂加速了治疗方案的分化，鼓励临床医生针对传统疗法难以覆盖的患者亚群，考虑针对特异性机制的治疗方案。同时，监管政策也日趋简化，使得临床整合速度更快，因为可靠的生物标记和真实世界证据推动了新药核准策略和适应症扩展。

药物经济学因素日益凸显，迫使製造商透过比较有效性、耐久性、患者报告结果等来证明其价值，而不仅依赖临床疗效终点。分销和交付创新，例如专科药房的扩张、家庭给药途径和数位化依从性支持，正在改变患者与其治疗方法的互动方式。因此，商业性成功越来越依赖一种综合方法，该方法将临床差异化与长期效用的确凿证据、以患者为中心的交付解决方案以及与付款人一致的价值提案相结合。这种转型正在为整个治疗生态系统创造机会和竞争压力。

未来十年中期美国关税变化对牛皮癣药物供应链、筹资策略和商业性准入动态的累积影响

近期，美国推出或调整医药原料和成品关税结构的政策，为全球银屑病药物供应链带来了新的复杂性。针对活性药物成分、生物製药成分和辅助材料的关税变化，可能会增加依赖国际采购的製造商的本地采购成本，促使其重新评估供应商组合和物流策略。为此，企业正在评估近岸外包、双重采购和合约对冲等措施，以稳定原料供应并保障生产连续性。

除了直接的成本影响外，关税还可能透过提高供应链韧性来影响产品上市时间和市场进入活动的顺序。跨境临床试验供应物流可能需要额外的海关规划和紧急库存，以确保入组时间。同时，拥有垂直整合或国内生技药品生产能力的製造商可能会在成本可预测性和监管合规性方面获得策略优势。重要的是，付款人和采购相关人员对持续的定价压力非常敏感，这可能会影响处方集动态和合约谈判，从而影响製造商在回扣、风险分担协议和患者援助计划方面的策略。

摘要：关税将成为更广泛的供应链现代化和製造业地理多元化的催化剂。因此，建议相关人员采取整体视角，在短期营运观点与製造敏捷性、替代采购和合作安排方面的长期投资之间取得平衡，以减少贸易政策波动的影响。

全面的细分主导洞察，将策略重点与治疗层级、给药途径、患者表型、人口统计、分销管道和医疗保健环境联繫起来

深入了解银屑病市场的细分情况，有助于产品开发、临床定位和商业性运作。生物製药包括IL-17抑制剂、IL-23抑制剂和TNF抑制剂等标靶药物，而小分子药物则包括JAK抑制剂、PDE4抑制剂等。每类药物的疗效、安全性、剂量和生产流程均有差异，这些因素会影响临床医师的选择和报销谈判。

给药途径是决定病患偏好和医疗保健系统工作流程的关键因素，涵盖注射剂、口服剂和外用剂。注射剂进一步分为静脉注射和皮下注射，每种注射剂都有其独特的临床监测和给药基础设施需求。口服剂包括胶囊、混悬液和锭剂，其给药便利性和药物动力学特征各不相同。患者病情严重程度分为轻度至中度或中度至重度，决定了升级途径以及全身性治疗和生物製药的适应症。

干癣在临床上表现为不同的亚型，包括红皮病型、斑块状干癣、逆性干癣、指甲干癣、斑块状干癣、脓疱型干癣和头皮干癣，这些表型通常需要差异化的治疗策略和疗效指标。患者群体涵盖成人、老年人和儿童，每种族群都有其独特的安全性和剂量考量，这些因素会影响附加檔、研究设计和市场定位。分销管道影响药物的可及性和支持，包括医院药房、线上药房、零售店和专科药房，它们在报销调整和病患教育方面发挥着各种作用。最后，治疗环境涵盖居家照护、医院管理以及皮肤科专科诊所，这些环境塑造了服务提供模式、依从性支援和远端监控机会。这些细分领域必须整合到临床开发计划、上市策略和付款人参与框架中，以确保与现实世界的治疗途径和相关人员的需求保持一致。

美洲、欧洲、中东和非洲以及亚太地区的区域动态影响监管策略、取得途径和商业化方法

美洲、欧洲、中东和非洲以及亚太地区的区域动态持续影响研发重点、监管计画和商业策略。在美洲，成熟的法规环境和成熟的专业医疗网络有利于快速引入创新生技药品和先进的支援服务，而付款人谈判和处方集的投放仍然至关重要。在该地区，临床医生网络和患者支持管道通常支持高效疗法的早期采用模式，而报销机制则要求明确证明长期效益。

欧洲、中东和非洲的法律规范分散，支付系统多样，因此需要製定区域性客製化的价值剂量和真实世界证据策略，以确保药物的可及性。平行的监管路径和对卫生技术评估的严格审查通常需要比较疗效和成本效益的证据，这迫使製造商在多个国家/地区产生数据并製定差异化的定价策略。此外，某些市场的供应链限制会影响分销选择以及对本地伙伴关係策略的需求。

亚太市场呈现已开发都市区快速采用和新兴市场准入不均衡的异质性组合。监管时间表和国内製造政策可能会影响上市定序，具有不同基因或表型特征的患者群体可能需要有针对性的临床证据。在所有地区，专科药房、数位互动工具和家庭护理解决方案日益重要的作用正在再形成患者病人历程，要求製造商建立本地定制的患者支援和商业模式。这些区域差异应指南上市资源、证据产生和经销伙伴关係的优先排序。

企业级策略着重于银屑病药物的临床差异化、製造敏捷性、支付方一致的证据生成以及以患者为中心的商业化

活跃于银屑病药物领域的大型製药和生物技术公司需要应对各种复杂因素，例如临床差异化、生产需求和付款人合作。成熟的生技药品开发商正在加大对下一代白细胞介素标靶药物及其生命週期管理的投资，而规模较小的生物技术公司则专注于创新的作用机制和生物标记主导的适应症。同时，专科製药公司正在开发口服小分子药物，重点关注给药的便利性和联合用药策略，以满足寻求注射以外治疗方案的患者亚群的需求。在这些多元化的公司中，策略重点都集中在证明持续疗效、提高安全性以及透过交付和支援方面的创新来优化患者体验。

在营运方面，企业正在加强製造敏捷性，并与合约研究和受託製造厂商合作，以确保生技药品的生产能力，并确保快速扩大临床和商业供应规模。在商业方面，企业正在投资真实世界结果研究和长期安全监测，以使证据生成与付款人的期望保持一致。与专业药房和数位医疗供应商的合作日益普遍，以支持依从性、远端监控和病患教育。成熟的企业通常利用全球网路来加快监管提交和市场进入的速度，而新兴参与企业则优先考虑利基差异化、策略伙伴关係和有针对性的临床项目，以在特定患者群体中站稳脚跟。在这种竞争激烈的环境中，治疗方法创新必须以强大的供应、证据和以病人为中心的商业化能力为支持。

产业领导者可采取的策略重点是协调临床差异化、製造弹性、付款人参与度和以病人为中心的商业化，以获得持久的成功

为了在不断变化的银屑病领域取得成功，行业领导者应采取多管齐下的策略，在科研投入、务实的商业运营和付款人参与之间取得平衡。优先考虑将清晰的机制差异化与强大的安全性和耐久性终点相结合的开发项目，并设计能够记录患者报告结果和真实世界疗效的临床试验，以支持整体价值陈述。同时，投资于生产弹性，包括区域产能和可行的替代供应商，以减轻贸易政策波动带来的风险，并确保临床和商业供应的不间断。

为了使证据产生与报销预期相符，我们与付款方和医疗技术评估机构进行早期和反覆的合作，以建立创新的合约安排，共担风险并证明疗效的相关性。我们与专业药房和数位医疗服务提供者建立伙伴关係，以增强依从性、远端监控和家庭管理能力，并投资于分销和患者支援生态系统。最后，我们实施在地化的上市方案，根据当地系统特点客製化监管提交、定价策略和病人参与，同时保持全球证据的一致性。透过将临床卓越性与营运韧性以及以付款方为中心的价值证明相结合，组织可以建立一条通往持续应用和有意义的患者疗效的可靠途径。

支持报告策略和营运结论的调查方法的详细信息，包括对关键专家的调查、对次要证据的三角测量以及基于情景的分析

本研究整合了对一手资料和二手资料的结构化审查、专家咨询和定性分析，以确保研究结果严谨可靠。主要资讯包括对临床意见领袖、付款方、供应链专家和商业高管的访谈，以提供有关治疗采用、报销动态和营运限制的背景资讯。二手资料研究涵盖同行评审的临床文献、监管指南文件、上市公司揭露资讯和生产技术文献，以支持临床机制、安全考量和生产现状。

此分析方法结合了定性输入的主题综合、监管和临床证据的交叉检验以及基于情境的供应链和政策影响评估。调查方法和资料来源强调资料来源的透明度、对不同资讯来源的仔细三角测量以及对营运风险因素的敏感度分析。为了尽可能减少偏见，研究结果由多个独立资讯来源证实，并由专家评审员检验临床解读和策略影响。具体而言，该分析着重于结构、临床和营运动态，而非定量市场预测。这种方法支持为策略规划、产品开发优先排序和证据产生策略提供可行的见解。

对研究结果的全面回顾强调了整合科学创新、营运弹性、付款人一致的证据和以患者为中心的服务以实现治疗效果的必要性。

总而言之，银屑病药物领域在提供科研机会的同时也增加了营运和商业性的复杂性。生物製药和标靶小分子药物的进展提高了治疗标准，但要成功地将这些进展转化为持续的患者获益，需要製定一个综合策略，将证据生成、生产韧性和以支付方为中心的价值展示融为一体。相关人员必须认识到，单靠临床差异化是不够的，还需要在供应链敏捷性、以患者为中心的交付机制以及能够证明长期疗效的真实世界证据项目方面进行同步投资。

展望未来，那些积极主动地将临床开发与切实可行的可及性策略和强大的患者支持模式相结合的公司，将更有能力应对监管多样性和付款人需求。此外，那些调整供应网络以降低政策和贸易风险的公司，将在产品上市执行和供应连续性方面获得竞争优势。最终，将科学创新与卓越营运和策略合作相结合的整体方法，将实现永续的商业性绩效，同时推动患者照护的显着改善。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 白细胞介素抑制剂的日益普及正在改变中度至重度牛皮癣的治疗模式
• 生物相似药替代品的出现促进了慢性牛皮癣治疗中具有成本效益的选择
• JAK抑制剂安全性资料的重要性日益提升，再形成了处方医师对新型干癣治疗的信心
• 整合数位健康平台，提高病患依从性和干癣远端监测
• 透过对牛皮癣患者的生物标记研究扩大个人化医疗努力
• 增加远距皮肤病学服务的可用性，并改善服务不足地区获得牛皮癣治疗的机会

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 银屑病药物市场（依药物类别）

• 生物製药
  • IL-17抑制剂
  • IL-23抑制剂
  • TNF抑制剂
• 小分子
  • JAK抑制剂
  • PDE4抑制剂

9. 牛皮癣药物市场（依给药途径）

• 注射
  • 静脉
  • 皮下
• 口服
  • 胶囊
  • 暂停
  • 药片
• 外用
  • 奶油
  • 形式
  • 凝胶
  • 软膏

第 10 章 银屑病药物市场（依患者严重程度）

• 轻度至中度
• 中度至重度

第11章 银屑病药物市场（依银屑病类型）

• 红皮病型干癣
• 水滴状干癣
• 反向型干癣
• 指甲牛皮癣
• 斑块型干癣
• 脓疱型干癣
• 头皮牛皮癣

第十二章 银屑病药物市场（依患者类型）

• 成人
• 老年人
• 孩子们

第十三章 银屑病药物市场（依分销管道）

• 医院药房
• 网路药局
• 零售药局
• 专业药房

第十四章 银屑病药物市场（依治疗环境）

• 家庭治疗
• 医院护理
• 专科皮肤科诊所

第十五章 银屑病药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十六章 银屑病药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十七章 银屑病药物市场（依国家）

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十八章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • AbbVie Inc.
  • Johnson & Johnson
  • Novartis AG
  • Amgen Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • UCB SA
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA

The Psoriasis Drugs Market is projected to grow by USD 27.63 billion at a CAGR of 12.41% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 10.83 billion
Estimated Year [2025]	USD 12.18 billion
Forecast Year [2032]	USD 27.63 billion
CAGR (%)	12.41%

An authoritative introduction summarizing the current therapeutic modalities, systemic pressures, and strategic questions shaping psoriasis drug development and commercialization

The psoriasis therapeutics landscape has entered a phase defined by rapid scientific progress and shifting commercial dynamics. Advances in targeted biologic agents and oral small molecules have expanded therapeutic options and raised expectations for improved efficacy, remission durability, and patient convenience. At the same time, payer scrutiny, supply chain complexity, and evolving regulatory expectations require manufacturers and healthcare providers to adapt operational and commercial approaches. Consequently, industry stakeholders must reconcile clinical promise with pragmatic considerations including manufacturing scalability, real-world safety monitoring, and differentiated value communication.

This introduction frames the subsequent analysis by summarizing the current therapeutic modalities, the principal clinical and commercial pressures, and the strategic questions that companies, clinicians, and payers are now confronting. It outlines how therapeutic classification, administration route, patient severity, psoriasis subtype, patient demographics, distribution channels, and treatment settings collectively shape adoption pathways and long-term care models. By situating recent innovations within realistic implementation constraints, this section prepares readers to assess strategic options, anticipate operational bottlenecks, and prioritize investments that will deliver sustained clinical and commercial returns.

Transformative clinical, regulatory, and commercial shifts are converging to redefine therapeutic differentiation, access pathways, and value demonstration in psoriasis care

The psoriasis treatment paradigm is being reshaped by converging scientific breakthroughs, regulatory evolution, and patient expectations for personalized care. Biologics targeting interleukin pathways and orally administered targeted inhibitors have accelerated therapeutic differentiation, leading clinicians to consider mechanism-specific choices for patient subgroups previously underserved by older treatments. Concurrently, regulatory pathways are accommodating more streamlined approval strategies for novel agents and for label expansions based on robust biomarker and real-world evidence, enabling faster clinical integration.

Pharmacoeconomic considerations have gained prominence, compelling manufacturers to demonstrate value through comparative effectiveness, durability, and patient-reported outcomes rather than relying solely on clinical efficacy endpoints. Distribution and delivery innovations, including increased use of specialty pharmacies, home-based administration pathways, and digital adherence supports, are altering how patients engage with treatment regimens. As a result, commercial success increasingly depends on an integrated approach that aligns clinical differentiation with robust evidence of long-term benefit, patient-centric delivery solutions, and payer-aligned value propositions. These transformative shifts are creating both opportunities and heightened competitive pressures across the therapeutic ecosystem.

Cumulative implications of evolving United States tariff measures on psoriasis drug supply chains, sourcing strategies, and commercial access dynamics through mid-decade

Recent policy developments introducing or adjusting United States tariff structures for pharmaceutical inputs and finished products have introduced new layers of complexity into global psoriasis drug supply chains. Tariff changes targeting active pharmaceutical ingredients, biologic components, and ancillary materials have the potential to increase landed costs for manufacturers that rely on international sourcing, prompting reassessments of supplier portfolios and logistics strategies. In response, organizations are evaluating nearshoring, dual-sourcing, and contractual hedges to stabilize input availability and protect production continuity.

Beyond direct cost implications, tariffs can influence the timing of product launches and the sequencing of market access activities by shifting operational priorities toward supply-chain resilience. Clinical trial supply logistics that span borders may require additional customs planning and contingency stock to maintain enrollment schedules. Meanwhile, manufacturers with vertically integrated production or domestic biologics manufacturing capabilities may find strategic advantages in cost predictability and regulatory alignment. Importantly, payers and procurement stakeholders are sensitive to any sustained pricing pressures that could affect formulary dynamics and contracting negotiations, which in turn influences manufacturer strategies for rebates, risk-sharing agreements, and patient support programs.

In summary, tariffs act as a catalyst for broader supply-chain modernization and geographic diversification of manufacturing. Stakeholders are therefore advised to adopt a holistic view that balances near-term operational responses with longer-term investments in manufacturing agility, alternative sourcing, and collaborative agreements that mitigate exposure to trade policy volatility.

Comprehensive segmentation-driven insights linking therapeutic class, administration route, patient phenotype, demographics, distribution channels, and care settings to strategic priorities

A nuanced understanding of how the psoriasis market segments informs product development, clinical positioning, and commercial engagement. Therapeutic classification differentiates between biologic therapies and small-molecule agents; biologics encompass targeted classes such as IL-17 inhibitors, IL-23 inhibitors, and TNF inhibitors, while small molecules include JAK inhibitors and PDE4 inhibitors. Each class carries distinct efficacy, safety, administration, and manufacturing considerations that influence clinician selection and reimbursement discussions.

Route of administration is a critical determinant of patient preference and health-system workflows, spanning injectable, oral, and topical modalities. Injectable formulations are further categorized by intravenous and subcutaneous delivery, each with unique clinical monitoring and administration infrastructure requirements; oral options include capsules, suspensions, and tablets that vary in dosing convenience and pharmacokinetic profiles; topical therapies are formulated as creams, foams, gels, or ointments tailored to lesion characteristics and patient adherence. Patient severity divides the landscape into mild-to-moderate and moderate-to-severe presentations, guiding escalation pathways and eligibility for systemic or biologic therapies.

Psoriasis manifests in clinically distinct subtypes including erythrodermic, guttate, inverse, nail, plaque, pustular, and scalp presentations, and these phenotypes often necessitate differentiated therapeutic strategies and outcome metrics. Patient demographics span adults, geriatric populations, and pediatric cohorts, each with unique safety and dosing considerations that affect labeling, trial design, and market positioning. Distribution channels influence access and support structures, encompassing hospital pharmacies, online pharmacies, retail outlets, and specialty pharmacies that play varying roles in reimbursement coordination and patient education. Finally, treatment settings range from home-based care to hospital-based management and specialty dermatology clinics, shaping service delivery models, adherence supports, and opportunities for remote monitoring. Collectively, these segmentation dimensions should be integrated into clinical development plans, commercial launch strategies, and payer engagement frameworks to ensure alignment with real-world treatment pathways and stakeholder needs.

Region-specific dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that influence regulatory strategy, access pathways, and commercialization approaches

Regional dynamics continue to shape development priorities, regulatory planning, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a mature regulatory environment and established specialty care networks favor rapid uptake of innovative biologics and advanced support services, alongside ongoing emphasis on payer negotiations and formulary placement. Clinician networks and patient advocacy channels in this region frequently drive early adoption patterns for high-efficacy therapies, while reimbursement mechanisms require clear demonstration of long-term benefit.

In Europe, Middle East & Africa, fragmented regulatory frameworks and diverse payer systems necessitate regionally tailored value dossiers and real-world evidence strategies to secure access. Parallel regulatory pathways and heightened health-technology assessment scrutiny often demand comparative effectiveness and cost-effectiveness evidence, prompting manufacturers to plan multi-country data generation and differentiated pricing strategies. In addition, supply-chain constraints in some markets influence distribution choices and the need for local partnership strategies.

Asia-Pacific markets display a heterogeneous mix of rapid adoption in advanced urban centers and variable access across emerging markets. Regulatory timelines and domestic manufacturing policies can influence launch sequencing, and patient populations with distinct genetic or phenotypic characteristics may require targeted clinical evidence. Across all regions, the increasing role of specialty pharmacies, digital engagement tools, and home-based treatment solutions is reshaping patient journeys and requiring manufacturers to craft region-sensitive patient support and commercial models. These regional nuances should guide prioritization of launch resources, evidence generation, and distribution partnerships.

Company-level strategies emphasizing clinical differentiation, manufacturing agility, payer-aligned evidence generation, and patient-centric commercialization in psoriasis therapeutics

Leading pharmaceutical and biotech companies active in psoriasis therapeutics are navigating a complex mix of clinical differentiation, manufacturing demands, and payer engagement. Established biologics developers are intensifying investments in next-generation interleukin-targeting agents and lifecycle management, while smaller biotechs focus on innovative mechanisms of action and biomarker-driven indications. Concurrently, specialty pharmaceutical firms are advancing oral small molecules that emphasize ease of administration and combination strategies to address patient subgroups seeking non-injectable options. Across these varied company profiles, strategic priorities coalesce around demonstrating durable efficacy, improving safety profiles, and optimizing patient experience through delivery and support innovations.

Operationally, companies are strengthening manufacturing agility and partnering with contract development and manufacturing organizations to secure biologics capacity and ensure rapid scale-up for clinical and commercial supply. Commercially, organizations are aligning evidence generation with payer expectations by investing in real-world outcomes research and longitudinal safety monitoring. Collaboration with specialty pharmacies and digital health vendors is increasingly common to support adherence, remote monitoring, and patient education. Mature players often leverage global networks to expedite regulatory filings and market entry, while emerging entrants prioritize niche differentiation, strategic partnerships, and targeted clinical programs to gain footholds in specific patient segments. The combined effect is a competitive environment where therapeutic innovation must be matched by robust supply, evidence, and patient-centric commercialization capabilities.

Actionable strategic priorities for industry leaders to align clinical differentiation, manufacturing resilience, payer engagement, and patient-centric commercialization for durable success

Industry leaders should adopt a multi-pronged strategy that balances scientific investment with pragmatic operations and payer engagement to prosper in the evolving psoriasis landscape. Prioritize development programs that pair clear mechanistic differentiation with robust safety and durability endpoints, and design clinical trials that capture patient-reported outcomes and real-world effectiveness dimensions to support comprehensive value narratives. Simultaneously, commit resources to manufacturing flexibility, including regional capacity and validated alternate suppliers, to reduce exposure to trade policy fluctuations and to support uninterrupted clinical and commercial supply.

Engage early and iteratively with payers and health-technology assessment bodies to align evidence generation with reimbursement expectations, and structure innovative contracting arrangements that share risk and demonstrate outcome linkage. Invest in distribution and patient-support ecosystems by cultivating partnerships with specialty pharmacies and digital health providers that enhance adherence, remote monitoring, and home-based administration capabilities. Finally, implement a regionalized market-entry playbook that tailors regulatory submissions, pricing strategies, and patient engagement to local system characteristics while preserving global evidence coherence. By integrating clinical excellence with operational resilience and payer-centric value demonstration, organizations can create defensible pathways to sustained adoption and meaningful patient outcomes.

Methodology detailing primary expert engagements, secondary evidence triangulation, and scenario-based analyses underpinning strategic and operational conclusions in the report

This research synthesizes a structured review of primary and secondary sources, expert consultations, and qualitative analyses to ensure rigorous and defensible findings. Primary inputs included interviews with clinical thought leaders, payers, supply-chain specialists, and commercial executives who provided context on treatment adoption, reimbursement dynamics, and operational constraints. Secondary research encompassed peer-reviewed clinical literature, regulatory guidance documents, public company disclosures, and technical manufacturing references to corroborate clinical mechanisms, safety considerations, and production realities.

Analytical methods integrated thematic synthesis of qualitative inputs, cross-validation of regulatory and clinical evidence, and scenario-based assessment of supply-chain and policy impacts. The methodology emphasized transparency in data provenance, careful triangulation of diverse information sources, and sensitivity analyses for operational risk factors. Where possible, findings were corroborated with multiple independent sources to reduce bias, and expert reviewers provided validation of clinical interpretations and strategic implications. Limitations are acknowledged; specifically, the analysis focuses on structural, clinical, and operational dynamics rather than quantitative market projections. The approach supports actionable insights for strategic planning, product development prioritization, and evidence generation strategies.

Concluding synthesis highlighting the imperative to integrate scientific innovation, operational resilience, payer-aligned evidence, and patient-centric delivery to realize therapeutic impact

In conclusion, the psoriasis therapeutics landscape offers substantial scientific opportunity coupled with heightened operational and commercial complexity. Advances in biologics and targeted small molecules have raised the standard of care, yet successful translation into sustained patient benefit requires comprehensive strategies that integrate evidence generation, manufacturing resilience, and payer-aligned value demonstration. Stakeholders must recognize that clinical differentiation alone is insufficient without parallel investments in supply-chain agility, patient-centric delivery mechanisms, and real-world evidence programs that substantiate long-term outcomes.

Moving forward, companies that proactively align clinical development with pragmatic access strategies and robust patient support models will be best positioned to navigate regulatory heterogeneity and payer demands. Moreover, organizations that adapt supply networks to mitigate policy and trade risks can secure competitive advantages in launch execution and continuity of supply. Ultimately, a holistic approach that marries scientific innovation with operational excellence and strategic collaborations will drive meaningful improvements in patient care while enabling sustainable commercial performance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of interleukin inhibitors transforming moderate to severe psoriasis treatment landscapes
• 5.2. Emergence of biosimilar alternatives driving cost-effective options for chronic psoriasis management
• 5.3. Growing emphasis on JAK inhibitor safety data reshaping prescriber confidence in new psoriasis therapies
• 5.4. Integration of digital health platforms enhancing patient adherence and remote monitoring for psoriasis
• 5.5. Expansion of personalized medicine initiatives driven by biomarker research in psoriatic patients
• 5.6. Increasing availability of teledermatology services improving access to psoriasis care in underserved regions

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Psoriasis Drugs Market, by Drug Class

• 8.1. Biologics
  • 8.1.1. IL 17 Inhibitors
  • 8.1.2. IL 23 Inhibitors
  • 8.1.3. TNF Inhibitors
• 8.2. Small Molecules
  • 8.2.1. JAK Inhibitors
  • 8.2.2. PDE4 Inhibitors

9. Psoriasis Drugs Market, by Route Of Administration

• 9.1. Injectable
  • 9.1.1. Intravenous
  • 9.1.2. Subcutaneous
• 9.2. Oral
  • 9.2.1. Capsules
  • 9.2.2. Suspensions
  • 9.2.3. Tablets
• 9.3. Topical
  • 9.3.1. Creams
  • 9.3.2. Foams
  • 9.3.3. Gels
  • 9.3.4. Ointments

10. Psoriasis Drugs Market, by Patient Severity

• 10.1. Mild To Moderate
• 10.2. Moderate To Severe

11. Psoriasis Drugs Market, by Psoriasis Type

• 11.1. Erythrodermic Psoriasis
• 11.2. Guttate Psoriasis
• 11.3. Inverse Psoriasis
• 11.4. Nail Psoriasis
• 11.5. Plaque Psoriasis
• 11.6. Pustular Psoriasis
• 11.7. Scalp Psoriasis

12. Psoriasis Drugs Market, by Patient Type

• 12.1. Adults
• 12.2. Geriatric
• 12.3. Pediatric

13. Psoriasis Drugs Market, by Distribution Channel

• 13.1. Hospital Pharmacies
• 13.2. Online Pharmacies
• 13.3. Retail Pharmacies
• 13.4. Specialty Pharmacies

14. Psoriasis Drugs Market, by Treatment Setting

• 14.1. Home-Based Treatment
• 14.2. Hospital-Based Care
• 14.3. Specialty Dermatology Clinics

15. Psoriasis Drugs Market, by Region

• 15.1. Americas
  • 15.1.1. North America
  • 15.1.2. Latin America
• 15.2. Europe, Middle East & Africa
  • 15.2.1. Europe
  • 15.2.2. Middle East
  • 15.2.3. Africa
• 15.3. Asia-Pacific

16. Psoriasis Drugs Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Psoriasis Drugs Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Share Analysis, 2024
• 18.2. FPNV Positioning Matrix, 2024
• 18.3. Competitive Analysis
  • 18.3.1. AbbVie Inc.
  • 18.3.2. Johnson & Johnson
  • 18.3.3. Novartis AG
  • 18.3.4. Amgen Inc.
  • 18.3.5. Eli Lilly and Company
  • 18.3.6. Pfizer Inc.
  • 18.3.7. UCB S.A.
  • 18.3.8. Merck & Co., Inc.
  • 18.3.9. Bristol-Myers Squibb Company
  • 18.3.10. Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. EUROPE PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. MIDDLE EAST PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. AFRICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASIA-PACIFIC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASEAN PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GCC PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. EUROPEAN UNION PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. BRICS PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. G7 PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. NATO PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. PSORIASIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 34. PSORIASIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. PSORIASIS DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL PSORIASIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 17 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY IL 23 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY JAK INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PDE4 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SUSPENSIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY FOAMS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY MODERATE TO SEVERE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ERYTHRODERMIC PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GUTTATE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY INVERSE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY NAIL PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PUSTULAR PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SCALP PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOME-BASED TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY HOSPITAL-BASED CARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY SPECIALTY DERMATOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL PSORIASIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 259. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 260. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 261. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 262. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 263. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 264. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 265. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
• TABLE 266. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
• TABLE 267. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 268. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 269. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 270. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 271. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 272. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 273. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 274. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 275. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
• TABLE 276. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
• TABLE 277. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
• TABLE 278. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
• TABLE 279. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 280. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 281. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 282. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 283. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
• TABLE 284. AMERICAS PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
• TABLE 285. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 286. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 287. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 288. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 289. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 290. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 291. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
• TABLE 292. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
• TABLE 293. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 294. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 295. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 296. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 297. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 298. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 299. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 300. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 301. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
• TABLE 302. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
• TABLE 303. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
• TABLE 304. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
• TABLE 305. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 306. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 307. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 308. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 309. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
• TABLE 310. NORTH AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
• TABLE 311. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 312. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 313. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 314. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 315. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
• TABLE 316. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY BIOLOGICS, 2025-2032 (USD MILLION)
• TABLE 317. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2018-2024 (USD MILLION)
• TABLE 318. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY SMALL MOLECULES, 2025-2032 (USD MILLION)
• TABLE 319. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 320. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 321. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
• TABLE 322. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
• TABLE 323. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
• TABLE 324. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
• TABLE 325. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
• TABLE 326. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
• TABLE 327. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2018-2024 (USD MILLION)
• TABLE 328. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT SEVERITY, 2025-2032 (USD MILLION)
• TABLE 329. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2018-2024 (USD MILLION)
• TABLE 330. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PSORIASIS TYPE, 2025-2032 (USD MILLION)
• TABLE 331. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 332. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 333. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 334. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 335. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2018-2024 (USD MILLION)
• TABLE 336. LATIN AMERICA PSORIASIS DRUGS MARKET SIZE, BY TREATMENT SETTING, 2025-2032 (USD MILLION)
• TABLE 337. EUROPE, MIDDLE EAST & AFRICA PSORIASIS DRUGS MARKET SIZE, BY SU